screen-detected cancers that a double-arm trial could show a fivefold difference in survival (between symptomatic lung cancers in the US or British national data (8 -15%) and 80% actuarial 10-year survival in the IELCAP study) and yet no reduction in lung cancer-specific mortality.
To support this hypothesis, Reich estimates that the incidence of overdiagnosed lung cancer is around 50%. In fact, to explain this markedly improved survival without reduced deaths, more than 75% of CT-screen detected lung cancers would have to be nonlethal.
In the case of prostate cancer, for which the existence of a substantial number of very slow-growing cancers has been well established, a recent publication from the National Cancer Institute (NCI) estimates that the incidence of overdiagnosis is approximately 23% (Welch and Albertsen, 2009 ). Reich therefore asks the reader to accept that the incidence of overdiagnosed lung cancer could double that of prostate cancer. But there is no reliable direct evidence to document any substantial lung cancer overdiagnosis. Three 1986 publications from Alvan Feinstein describing 'postmortem-surprise lung cancers' were funded by the notorious Council for Tobacco Research and are often cited in defence against medical monitoring lawsuits (McFarlane et al, 1986a (McFarlane et al, , b, 1987 . Symptom-detected but untreated stage I patients die, almost always, within 5 years (Raz et al, 2007) . The same is true of untreated patients detected by screening roentgenograms and CT scans (Sobue et al, 1992 ).
Reich's hypothesis would be cause for amusement if not for the cost. We refer not to the $200 million price tag of the NCI's National Lung Screen Trial, but to the unnecessary suffering and death of thousands of individuals from lung cancer who might have been salvaged by screening, between today and the publication of prospective randomised trials. Is this a reasonable and humane cost to refute a preposterous hypothesis?
We suspect that a mindset that would consider such cost justifiable is what led Arthur Golleb to characterise epidemiology as 'the practice of medicine without the tears'.
